摩根大通表示，Kura Oncology不断增长的抗癌药销售额和前景良好的研发管线可能推动其股价上涨。
Kura Oncology 's growing cancer drug sales and promising pipeline could fuel a rally in its stock, according to JPMorgan.
该行分析师Priyanka Grover首次覆盖该股，给予“增持”评级，并设定年底目标价30美元，较周三10.71美元的收盘价意味着180%的上涨空间。周四股价上涨约1%。
Analyst Priyanka Grover initiated coverage with an overweight rating and a year-end price target of $30, implying 180% upside to Wednesday's close of $10.71. Shares were trading up about 1% on Thursday.
看多逻辑的核心在于，Komzifti于2025年11月获美国食品药品监督管理局批准，用于治疗携带NPM1突变、病情复发或对治疗无应答的成人急性髓系白血病后，Kura正转型为商业化阶段公司。
The bullish call centers on Kura's transition into a commercial-stage company after Komzifti received Food and Drug Administration approval in November 2025 for adults with acute myeloid leukemia carrying a NPM1 mutation whose cancer has returned or failed to respond to treatment.
Grover写道，Komzifti上市初期的销售情况表明医生正“积极采用”这种每日一次的口服药。
Early sales of the once-daily pill point to "aggressive physician adoption," Grover wrote.
自Komzifti正式商业上市以来，净产品收入从2025年最后五周的210万美元增至2026年第二季度的910万美元。
Since Komzifti's commercial launch, net product revenue has increased from $2.1 million in the final five weeks of 2025 to $9.1 million in the second quarter of 2026.
摩根大通认为，该药有望扩大至新诊断患者，并估计其在新诊断患者相关全球市场的潜在峰值销售额约为15亿美元。
JPMorgan sees an opportunity to expand its use to newly diagnosed patients, estimating roughly $1.5 billion in potential worldwide peak sales across those markets.
摩根大通表示，Kura“明确有望”在白血病市场占据可观份额。
Kura has "clear potential" to capture meaningful share of the leukemia market, JPMorgan said.
KURA年初至今走势——Kura Oncology的年初至今表现。
KURA YTD mountain Kura Oncology's YTD performance.
Grover的分部估值加总分析还评估了其实验性抗癌药darlifarnib的潜力，该药旨在阻断特定的肿瘤生长信号。摩根大通估计，该药的全球潜在峰值销售额可能达到6亿美元。
Grover's sum-of-the-parts analysis also weighs the potential of its experimental cancer drug, darlifarnib, which is designed to block specific tumor growth signals. JPMorgan estimates the drug could have $600 million in potential worldwide peak sales.
摩根大通表示，darlifarnib可为这家总部位于圣迭戈的公司带来“潜在的第二个肿瘤药业务板块”。
JPMorgan said darlifarnib provides the San Diego-based company with "a potential second oncology franchise."
Kura Oncology在4月公布的一项数据研究中表示，darlifarnib与卡博替尼（另一种用于治疗晚期癌症的靶向疗法）联合使用“展现出强劲的抗肿瘤活性”。
In an April data study, Kura Oncology said a combination of darlifarnib and cabozantinib, another targeted therapy to treat advanced cancers, "demonstrated robust antitumor activity."
摩根大通表示，随着临床试验推进以及市场更充分地认识这两种疗法的机会，Kura股价仍有“显著的上涨空间”。
Kura shares have "significant upside potential," JPMorgan said, as clinical trials progress and the market better appreciates opportunities from both treatments.